3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 3
6
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thrombocythemia, Essential
1
Recurrence
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Interventions
Imatinib Mesylate
18
Dasatinib
12
Cyclophosphamide
11
fludarabine phosphate
9
nilotinib
8
fludarabine
7
Sirolimus
6
ruxolitinib
5
Tacrolimus
5
Mycophenolic Acid
5
Cytarabine
5
Azacitidine
5
Whole-Body Irradiation
4
Ipilimumab
4
Busulfan
4
Bortezomib
4
thymoglobulin
3
bosutinib
3
belinostat
3
aldesleukin
3
Specimen Handling
3
Nivolumab
3
Interleukin-2
3
Granulocyte Colony-Stimulating Factor
3
Clofarabine
3
CTLA-4 Antigen
3
Antilymphocyte Serum
3
AP 1903 reagent
3
zileuton
2
tozasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Interferon-alpha
×
Clear all
NCT01220648
2015-05-05
NICOLI
Novartis
Phase 1
Completed
4 enrolled